42,599 Shares in Haemonetics Co. (NYSE:HAE) Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 42,599 shares of the medical instruments supplier's stock, valued at approximately $3,326,000. Susquehanna Fundamental Investments LLC owned about 0.08% of Haemonetics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of HAE. Arizona State Retirement System grew its stake in Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after buying an additional 181 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares during the period. HighTower Advisors LLC grew its position in shares of Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 244 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics in the 4th quarter worth about $25,000. Finally, Xponance Inc. lifted its position in Haemonetics by 5.9% in the 4th quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock valued at $566,000 after purchasing an additional 404 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Price Performance

Shares of HAE traded up $0.95 during mid-day trading on Friday, hitting $63.94. The company's stock had a trading volume of 534,756 shares, compared to its average volume of 690,673. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a 50-day moving average price of $62.76 and a 200 day moving average price of $71.82. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The stock has a market capitalization of $3.21 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, research analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on HAE. Raymond James restated a "strong-buy" rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. JMP Securities lowered their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reduced their price target on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.